An approach to interpreting immunohistochemical stains of adenocarcinoma in small needle core biopsy specimens: The impact of limited specimen size

American Journal of Clinical Pathology

Volumn 127, Issue 2, 2007, Pages 273-281

  Goldstein, Neal S ^a   Bosler, David ^a  

^a WILLIAM BEAUMONT HOSPITAL   (United States)

Author keywords

Adenocarcinoma; Antibody; Biopsy; Immunohistochemistry; Interpretation; Needle; Quality

Indexed keywords

CYTOKERATIN 20; CYTOKERATIN 7;

ADENOCARCINOMA; ARTICLE; COLORECTAL ADENOCARCINOMA; COLORECTAL CARCINOMA; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; IMAGING; IMMUNOCOMPETENT CELL; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LIVER RESECTION; METASTASIS; NEEDLE BIOPSY; PRIORITY JOURNAL; COLORECTAL TUMOR; HUMAN; INSTRUMENTATION; LIVER TUMOR; METHODOLOGY; NEEDLE; PATHOLOGY; SENSITIVITY AND SPECIFICITY;

ADENOCARCINOMA; BIOPSY, NEEDLE; COLORECTAL NEOPLASMS; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-20; KERATIN-7; LIVER NEOPLASMS; NEEDLES; SENSITIVITY AND SPECIFICITY;

EID: 33847045251     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/ATHVF5R4CQUKB7LX     Document Type: Article

References (32)

1. Lagendijk JH, Mullink H, Van Diest PJ, et al. Tracing the origin of adenocarcinomas with unknown primary using immunohistochemistry: differential diagnosis between colonic and ovarian carcinomas as primary sites. Hum Pathol. 1998;29:491-497.
2. Loy TS, Calaluce RD. Utility of cytokeratin immunostaining in separating pulmonary adenocarcinomas from colonic adenocarcinomas. Am J Clin Pathol. 1994;102:764-767.
3. Tot T. Adenocarcinomas metastatic to the liver: the value of cytokeratms 20 and 7 in the search for unknown primary tumors. Cancer. 1999;85:171-177.
4. Wauters CC, Smedts F, Gerrits LG, et al. Keratins 7 and 20 as diagnostic markers of carcinomas metastatic to the ovary. Hum Pathol. 1995;26:852-855.
5. Tot T, Samii S. The clinical relevance of cytokeratin phenotyping in needle biopsy of liver metastasis. APMIS. 2003;111:1075-1082.
6. Chen ZM, Wang HL. Alteration of cytokeratin 7 and cytokeratin 20 expression profile is uniquely associated with tumorigenesis of primary adenocarcinoma of the small intestine. Am J Surg Pathol. 2004;28:1352-1359.
7. McGregor DK, Wu TT, Rashid A, et al. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am J Surg Pathol. 2004;28:712-718.
8. Chu P, Wu E, Weiss LM. Cytokeratin 7 and cytokeratin 20 expression in epithelial neoplasms: a survey of 435 cases. Mod Pathol. 2000;13:962-972.
9. Kende AI, Carr NJ, Sobin LH. Expression of cytokeratins 7 and 20 in carcinomas of the gastrointestinal tract. Histopathology. 2003;42:137-140.
10. Ikeda S, Fujimori M, Shibata S, et al. Combined immunohistochemistry of beta-catenin, cytokeratin 7, and cytokeratin 20 is useful in discriminating primary lung adenocarcinomas from metastatic colorectal cancer. BMC Cancer. 2006;6:31.
11. Kummar S, Fogarasi M, Canova A, et al. Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma. Br J Cancer. 2002;86:1884-1887.
12. Wang NP, Zee S, Zarbo RJ, et al. Coordinate expression of cytokeratins 7 and 20 defines unique subsets of carcinomas. Appl Immunohistochem. 1995;3:99-107.
13. Berezowski K, Stastny JF, Kornstein MJ. Cytokeratins 7 and 20 and carcinoembryonic antigen in ovarian and colonic carcinoma. Mod Pathol. 1996;9:426-429.
14. Blumenfeld W, Turi GK, Harrison G, et al. Utility of cytokeratin 7 and 20 subset analysis as an aid in the identification of primary site of origin of malignancy in cytologic specimens. Diagn Cytopathol. 1999;20:63-66.
15. Ji H, Isacson C, Seidman JD, et al. Cytokeratins 7 and 20, Dpc4, and MUC5 AC in the distinction of metastatic mucinous carcinomas in the ovary from primary ovarian mucinous tumors: Dpc4 assists in identifying metastatic pancreatic carcinomas. Int J Gynecol Pathol. 2002;21:391-400.
16. Loy TS, Calaluce RD, Keeney GL. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol. 1996;9:1040-1044.
17. Maeda T, Kajiyama K, Adachi E, et al. The expression of cytokeratins 7, 19, and 20 in primary and metastatic carcinomas of the liver. Mod Pathol. 1996;9:901-909.
18. Park SY, Kim HS, Hong EK, et al. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum Pathol. 2002;33:1078-1085.
19. Rubin BP, Skarin AT, Pisick E, et al. Use of cytokeratins 7 and 20 in determining the origin of metastatic carcinoma of unknown primary, with special emphasis on lung cancer. Eur J Cancer Prev. 2001;10:77-82.
20. Tot T. Cytokeratins 20 and 7 as biomarkers: usefulness in discriminating primary from metastatic adenocarcinoma. Eur J Cancer. 2002;38:758-763.
21. Tot T. Identifying colorectal metastases in liver biopsies: the novel CDX2 antibody is less specific than the cytokeratin 20+/7- phenotype. Med Sci Monit. 2004;10:BR139-BR143.
22. Wassertheil-Smoller S. Biostaastics and Epidemiology. New York, NY: Springer-Verlag; 2004.
23. Fletcher RH, Fletcher SW. Clinical Epidemiology: The Essentials. Philadelphia, PA: Lippincott Williams & Wilkins; 2005.
24. Streiner DL, Norman GR. Measurement. In: PDQ Epidemiology. St Louis, MO: Mosby; 1996:79-117.
25. Altman DG, Bland JM. Standard deviations and standard errors. BMJ. 2005;331:903.
26. Altman DG, Royston P. The cost of dichotomising continuous variables. BMJ. 2006;332:1080.
27. Royston P, Altman DG, Sauerbrei W. Dichotomizing continuous predictors in multiple regression: a bad idea. Stat Med. 2006;25:127-141.
28. MacCallum RC, Zhang S, Preacher KJ, et al. On the practice of dichotomization of quantitative variables. Psychol Methods. 2002;7:19-40.
29. Austin PC, Brunner LJ. Inflation of the type I error rate when a continuous confounding variable is categorized in logistic regression analyses. Stat Med. 2004;23:1159-1178.
30. Altman DG, Lausen B, Sauerbrei W, et al. Dangers of using "optimal" cut-points in the evaluation of prognostic factors. J Natl Cancer Inst. 1994;86:829-835.
31. Buettner P, Garbe C, Guggenmoos-Holzmann I. Problems in defining cutoff points of continuous prognostic factors: example of tumor thickness in primary cutaneous melanoma. J Clin Epidemiol. 1997;50:1201-1210.
32. Del PG, Zandieh P, Lee MJ. Treatment of continuous data as categotic variables in obstetrics and gynecology. Obstet Gynecol. 1997;89:351-354.